ArticleClinical pharmacology and therapeutics2019
Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate.
Article in Clinical pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.
- Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada.Current oncology (Toronto, Ont.) · 2025Guideline
- Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.Nature communications · 2025Trial
- An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.Breast cancer research and treatment · 2022Trial
- Overview of pseudo-acute kidney injury.Renal failure · 2026Review
- Creatinine-Cystatin C Discrepancy and Renal Transporter Polymorphisms in Japanese Patients with Breast Cancer Receiving Abemaciclib.Clinical pharmacology and therapeutics · 2026Article
- Young Investigator Award 2026: Extent and incidence of pseudo-worsening of kidney function due to oral antitumor therapeutics in the AMBORA cohort: an analysis of real-world data.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Incidence and Magnitude of Pseudo-decrease in Kidney Function With Oral Epidermal Growth Factor Inhibitor Osimertinib.Kidney medicine · 2026Article
- Extent and Incidence of Pseudo-Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real-World Data.Clinical pharmacology and therapeutics · 2026Article
- Pseudo-Acute Kidney Injury With Tyrosine Kinase Inhibitors: Utility of the Creatinine-to-Cystatin C Ratio.Kidney international reports · 2026Article
- Review
- Distinct renal adverse event profiles among CDK4/6 inhibitors: a comparative pharmacovigilance analysis.Frontiers in pharmacology · 2026Article
- Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases.Frontiers in medicine · 2026Article
- Nephrotoxicity secondary to CDK 4/6 inhibitors in advanced breast cancer patients and its impact on survival.Therapeutic advances in medical oncology · 2026Article
- Afatinib-associated pseudo-acute kidney injury.Clinical kidney journal · 2025Article
- Molecularly Targeted Cancer Medications and Kidney Health.JAMA network open · 2025Article
- Oral Tamoxifen and Abemaciclib in Postoperative Therapy for Male Breast Cancer: A Case Report.The American journal of case reports · 2025Article
- Article
- Abemaciclib-associated acute interstitial nephritis successfully treated with glucocorticoids: a case report and literature review.BMC nephrology · 2025Review
- Acute kidney injury: pathogenesis and therapeutic interventions.Molecular biomedicine · 2025Review
- Ten tips for an onco-nephrology clinic.Clinical kidney journal · 2025Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6, is indicated for metastatic breast cancer treatment. Reversible increases in serum creatinine levels of ~15-40% over baseline have been observed following abemaciclib dosing. This study assessed the in vitro and clinical inhibition of renal transporters by abemaciclib and its metabolites using metformin (a clinically relevant transporter substrate), in a clinical study that quantified glomerular filtration and iohexol clearance. In vitro, abemaciclib inhibited metformin uptake by organic cation transporter 2, multidrug and toxin extrusion (MATE)1, and MATE2-K transporters with a half-maximal inhibitory concentration of 0.4-3.8 μM. Clinically, abemaciclib significantly increased metformin exposure but did not significantly affect measured glomerular filtration rate, serum neutrophil gelatinase-associated lipocalin (NGAL), serum cystatin-C, or the urinary markers of kidney tubular injury, NGAL and kidney injury molecule-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.